Pregnancy
WHO issues first pregnancy guideline for sickle cell disease

The WHO has released its first global guideline for managing sickle cell disease (SCD) during pregnancy, aiming to reduce health risks that can be life-threatening for women and babies.
The guideline addresses a major gap in care for the 7.7 million people living with SCD globally – a number that has increased by over 40 per cent since 2000.
SCD refers to a group of inherited blood disorders where red blood cells become abnormally shaped like crescents or sickles.
These misshapen cells can block blood flow, leading to severe anaemia, painful episodes, repeated infections and medical emergencies such as strokes, sepsis or organ failure.
Dr Doris Chou is medical officer and lead author of the guideline.
Chou said: “It’s essential that women with sickle cell disease can discuss their care options early in pregnancy—or ideally before—with knowledgeable providers.
“This supports informed decisions about any treatment options to continue or adopt, as well as agree on ways of handling potential complications, so as to optimise outcomes for the woman, her pregnancy, and her baby.”
The new guideline provides evidence-based recommendations tailored for low- and middle-income countries, where the majority of cases and deaths from the disease occur.
Sub-Saharan Africa accounts for around 80 per cent of global cases, with others found in parts of the Middle East, the Caribbean and South Asia.
With greater population movement and improved life expectancy, the sickle cell gene is becoming more widespread, increasing the need for awareness among maternity care providers.
During pregnancy, health risks from SCD increase due to greater demands on the body’s oxygen and nutrient supply.
Women with the condition are four to eleven times more likely to die from pregnancy-related causes than women without SCD.
They are also more prone to complications such as pre-eclampsia – a serious blood pressure disorder – while their babies face a higher risk of stillbirth, premature birth or low birth weight.
Dr Pascale Allotey is director for sexual and reproductive health and research at WHO and the United Nations’ Special Programme for Human Reproduction.
Allotey said:”With quality health care, women with inherited blood disorders like sickle cell disease can have safe and healthy pregnancies and births.
“This new guideline aims to improve pregnancy outcomes for those affected.
“With sickle cell on the rise, more investment is urgently needed to expand access to evidence-based treatments during pregnancy as well as diagnosis and information about this neglected disease.”
The guideline includes over 20 recommendations, covering areas such as folic acid and iron supplementation (with adjustments for malaria-endemic regions), management of sickle cell crises and pain, prevention of infections and blood clots, use of prophylactic blood transfusions, and additional monitoring of both the woman and the baby’s health throughout pregnancy.
It stresses the importance of personalised and respectful care, recognising each woman’s individual needs, medical history and preferences.
The guideline also highlights the need to tackle stigma and discrimination in healthcare settings, which remains a significant barrier to care in many countries.
Pregnancy
Pregnant women prioritised as NHS rolls out flu vaccine

Pregnant women are among the first groups offered the NHS flu vaccine this winter, which has been updated to better match the subclade K strain.
Schoolchildren are also being prioritised and, like pregnant women, can receive the vaccine from September because they can catch and spread flu easily.
Protecting them also helps others, including younger siblings and grandparents.
Other eligible groups, including people aged 65 and over, will be able to receive a free NHS flu vaccine from October and should receive an invitation by phone or post.
Dr Amanda Doyle from NHS England said: “Last year’s flu season came early and was made worse by a new variant, which had a major impact for patients and put enormous pressure on urgent and emergency care services across the country.
“With the NHS experiencing its busiest summer on record, staff have started preparing for this winter earlier than ever – and with services already under significant pressure, it is vital that everyone offered the vaccine comes forward.”
Last winter’s flu season began more than a month earlier than usual as a new mutated strain circulated.
The strain was sometimes referred to as “Super flu”, although this is not a medical term and does not mean the virus is harder to treat. The name reflected that people had yet to build up immunity against it.
Flu vaccines are updated each year to better match the influenza viruses expected to circulate. These viruses continually mutate, so experts must predict how they are likely to change.
This winter’s vaccine includes changes intended to provide a better match for subclade K.
It remains unclear when flu will begin circulating widely this winter or how severe the season will be. Experts often look at flu activity in southern hemisphere countries such as Australia and New Zealand for indications of how the UK season could develop.
Their flu season peaks in July or August. Australia has recorded fewer cases than last year, while New Zealand has experienced high numbers.
Everyone is at risk of catching flu, regardless of age or how fit and healthy they are.
Doyle said: “Flu can really knock you for six, and for some children and pregnant women it can mean becoming seriously ill or ending up in hospital.”
The flu vaccine cannot give you flu. Instead, it helps the body know how to fight the virus.
Children aged two and over receive a nasal spray version, while adults receive an injection. One dose is needed ahead of winter.
Free NHS flu vaccines are available through pharmacies, GPs and schools. People who are not eligible for a free vaccination can pay around £10 to £20.
Schoolchildren and pregnant women can receive a free NHS flu vaccine from September onwards.
From October, free vaccination will also be available to children aged two or older who have not yet started school, people aged 65 and over, those with certain long-term health conditions, care home residents and carers of older or disabled people, including those receiving a carer’s allowance.
It will also be available to people living with someone who has a weakened immune system and those experiencing homelessness or staying in a homeless hostel or night shelter.
More adults will also be offered vaccination against respiratory syncytial virus (RSV), a virus that attacks the lungs, this winter.
From September, adults with certain pre-existing health conditions, such as chronic lung disease, will be invited for the RSV vaccine when they turn 65 rather than waiting until 75.
Pregnancy
New universal heart attack definition could transform care for women
Entrepreneur
KOVE Medical raises €1.7 million to improve safety of foetal surgery

KOVE Medical has raised €1.7 million to support first-in-human studies of an implantable device designed to reduce preterm birth risk after foetal surgery.
The University of Zurich spin-off is developing a device designed to close defects left by surgical instruments following fetoscopy, a minimally invasive procedure performed inside the womb.
Fetoscopies can treat life-threatening conditions before birth but require surgical instruments to pass through the uterine wall and amniotic sac.
This can weaken the protective membrane, causing fluid leakage or rupture and often leading to preterm birth.
KOVE Medical said in a statement on LinkedIn: “This is a crucial step forward for our company, and we are incredibly grateful for the strong support and trust from our syndicate of visionary angel investors.”
KOVE Medical says its device closes the defect at the end of the procedure, stabilising the membrane and preventing complications. The aim is to make in-utero interventions safe enough to become a standard method of care.
The company plans to use the seed funding to reach first-in-human studies, a key milestone for a medical device seeking regulatory approval.
The CHF1.6m round was backed by a syndicate of angel investors.
pain conditions2 weeks agoMajor UK study could be a ‘game-changer’ for heavy periods and endometriosis
Entrepreneur7 days agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Fertility2 weeks agoOne week left to apply: W Accelerate with Merck KGaA and M Ventures
Pregnancy1 week agoUK study aims to transform maternity care for high-risk pregnancies
Menopause2 weeks agoQuarter of women miss work due to menstual symptoms, survey finds
Mental health2 weeks agoPMDD after SSRIs or hormones: Why the brain may be the missing treatment target
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Menopause5 days agoMenopause hormone treatment may ease brain fog, study suggests













